CClinicalTrials.gg
Not yet recruitingNCT07768982Updated Aug 17, 2026

Clinical Characteristics and Prognostic Factors in Patients With Meningitis at Sohag Governorate.

An observational study in Meningitis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Sex
All
01

Study summary

analyze the clinical characteristics and prognostic factors in patients with meningitis at Sohag Governorate .This is an ambidirectional (retrospective and prospective), hospital-based observational study. The study involves a retrospective review of patient records over the past 3 years, combined with a prospective recruitment of new patients for one year from the initiation of the study

02

Conditions studied

  • Meningitis

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients diagnosed with meningitis and admitted to Sohag Fever Hospital during the study period, regardless of age or sex, who meet the study eligibility criteria.

Inclusion criteria

  • All patients diagnosed with meningitis admitted to Sohag Fever Hospital during the study period.
  • Patients of all age groups and both sexes.
  • Patients with confirmed diagnosis based on clinical features and CSF analysis.

Exclusion criteria

Exclusion Criteria:

  • Patients with incomplete medical records.
  • Patients with uncertain diagnosis of meningitis.
  • Patients discharged against medical advice before completion of evaluation.
04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Target follow-up
2 Weeks
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. All-cause in-hospital mortality

    Death from any cause occurring during hospitalization, reported as the number and percentage of participants who died during hospital admission.

    Time frame: From hospital admission until hospital discharge, up to 30 days.

Secondary outcomes

  1. Recovery without neurological sequelae at hospital discharge

    Number and percentage of participants who recover from meningitis without documented neurological sequelae at hospital discharge.

    Time frame: From hospital admission until hospital discharge, up to 30 days.

  2. Neurological sequelae at hospital discharge

    Number and percentage of participants with documented neurological sequelae related to meningitis at hospital discharge.

    Time frame: From hospital admission until hospital discharge, up to 30 days.

  3. In-hospital complications

    Number and percentage of participants who develop complications during hospitalization, with the type of complication recorded.

    Time frame: From hospital admission until hospital discharge, up to 30 days.

06

Study locations

1 site
  • Sohag Fever Hospital
    Sohag, Egypt 20, Egypt
    • يحيي عاطف · Contact
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07768982
Lead sponsor
Sohag University
Responsible party
Yehia Atef Khalifa Elsayed (Resident of Gastroenterology and Hepatology, Sohag Fever Hospital, Sohag University) — Principal investigator
First posted
Aug 17, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

YEHIA ATEF
Contact
yehiaatef183@gmail.com
20010333109026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion